Whole-body magnetic resonance/diffusion-weighted sequence with background signal suppression (WB-MR/DWIBS) vs. 18F-FDG PET/CT in diagnosis of lymphoma

Gihan Hassan Gamal

Abstract

Background: The purpose of this study was to compare the performance of whole-body magnetic resonance/diffusion-weighted imaging with background signal suppression (WB-MR/DWIBS) method, with that of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT), for lesion detection and initial staging of patients with lymphoma using the histopathologically diagnosis as a reference standard.

Results: Thirty-two patients with newly pathologically proven lymphoma were enrolled in this prospective study from May 2018 to January 2020 (27 males, 5 females). All patients underwent PET/CT followed by WB-MR/DWIBS as an attempt to compare the performance of both methods for lesion detection and initial staging in patients with lymphoma.

The overall sensitivity, specificity, PPV, NPV, and accuracy of 18F-FDG-PET/CT vs WB-MR/DWIBS in correlation with reference standard data in detection of lymphoma were calculated for PET/CT 96%, 100%, 100%, 80%, and 97% while those of WB-MR/DWIBS were 93%, 76%, 96%, 61%, and 91%, respectively.

Conclusion: 18F-FDG PET/CT remains the standard reference of imaging in evaluation of lymphoma due to its higher sensitivity and specificity over WB-MR/DWIBS. Future studies with larger cohorts are necessary for better evaluation of the role of WB-MR/DWIBS in lymphoma patients. The current study highlights the potential complementary role of WB-MRI/DWIBS in the context of bone marrow involvement evaluation omitting unnecessary bone marrow biopsy.

Keywords: Lymphoma, Whole-body magnetic resonance with diffusion-weighted imaging with background signal suppression (WB-MR/DWIBS), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)

Background

Lymphoma is the most common primary hematopoietic malignancy which is also considered as one of the most curable forms of cancer [1]. It constitutes approximately 5% of new cancers worldwide, arising from mature or immature B cells, T cells, or natural killer cells at various stages of differentiation. Mature B cells lymphomas comprise over 90% of lymphoid neoplasm and include Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The most common types are follicular lymphoma and diffuse large B cells lymphoma [2]. After a histopathologically diagnosis has been established, the imaging-based initial staging will influence the choice of therapy and prognosis, aid in radiation therapy planning for localized disease, and provide a baseline for treatment response monitoring. HL and NHL staging is currently based on Cotswold’s modification of the Ann Arbor classification system. This system uses the number of tumor sites, the extent of involvement (nodal or
extra-nodal), and its distribution as staging factors, whereas Cotswold’s modification also take tumor burden as a complementary factor [3].

According to the biological behavior and consequently the prognosis, lymphoma can be grouped as low grade and aggressive (intermediate and high grade) tumors. The presence of extra-nodal disease has also prognostic implications as this may define a more advanced staging status (III or IV).

The accurate assessment of the initial extent of the disease determines the optimal treatment plan, and monitoring for treatment response, and guides the treatment duration and choice of therapeutic modality [4].

18-F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG-PET/CT) has been advocated as the method of choice for lymphoma staging since it enables whole-body analysis with high sensitivity detection of the affected areas, as it combines the capacities for anatomical and function assessment. The principle of the imaging test is based on metabolic changes that reflect fundamental differences in the central metabolic pathways in malignant tissue. Most cancer cells exhibit elevated levels of glycolysis, and this metabolic pathway seems to be related to a higher glucose uptake. As a result of those changes, tumor cells produce lactate at a higher levels compared to non-malignant tissues, even in the presence of oxygen, a phenomenon termed “aerobic glycolysis or the (Warburg effect) [5].

18F-FDG-PET/CT relies on this principle to detect foci of tumor proliferation. The level of FDG uptake can be evaluated using standardized uptake value (SUV). The SUV is the activity in the lesion measured. Higher FDG uptake values are seen in aggressive tumors compared to more indolent ones that usually show a very low glucose concentration. 18F-FDG PET/CT is the reference standard imaging modalities for patients affected by HL or aggressive NHL. However, there are some shortcomings to this technique amongst which are exposure of patients to ionizing radiation, contrast, and isotope agents [6].

Magnetic resonance imaging (MRI) has emerged as a safer non-invasive alternative for lymphoma staging, since progress in MRI technique now enables whole-body magnetic resonance with diffusion-weighted imaging with background signal suppression (WB-MR/DWIBS) as a good, radiation-free alternative. This method is based on the measurements of Brownian motion of water molecules in the biological tissue. In many pathological conditions, water diffusivity is impacted (low) due to increased neoplastic cellularity or swelling in inflammation or infectious lesions. It also concerns lymphomas, where cells are densely packed and randomly organized, inhibiting an effective motion of extracellular water. DWIBS provides cross-sectional imaging of the entire body, with a high soft tissue contrast, and functional information [7]. The apparent diffusion coefficient (ADC) can provide useful information on treatment response and help in distinguishing benign from malignant tissues. Based on that water molecules with large degree of motion or a great diffusion distance (e.g., within the intravascular space) will show signal attenuation with small b values (e.g., \(b = 50, = 100\) s/mm\(^2\)). By contrast, the large b values (e.g., = 1000 s/mm\(^2\)) are usually required to perceive slow-moving water molecules or small diffusion [8].

The purpose of this study was to compare the performance of (WB-MR/DWIBS) whole-body magnetic resonance/diffusion-weighted imaging with background signal suppression method, with that of (18F-FDG-PET/CT) 18F-fluorodeoxyglucose positron emission tomography/computed tomography for lesion detection and initial staging in patients with lymphoma using the histopathologically diagnosis as a reference standard.

**Methods**

**Patient’s selection and preparation**

We enrolled in this prospective study 32 patients with newly diagnosed lymphoma of different types over a period from May 2018 to January 2020, (27 males and 5 females) with age ranged from 16 to 60 years. All patients underwent routine evaluation include history, physical examination, and blood sugar test.

Exclusion criteria were contraindications to MRI, previous diagnosis of malignancy, patients with renal function impairment (serum creatinine > 2 mg/dL), patients with blood glucose level > 160 mg/dL, and patients received chemotherapy prior to the initial staging or in between the two techniques.

Patients underwent 18F-FDG PET/CT and WB-MRI-/DWIBS within 10 days of diagnosis and before starting the treatment. Staging was based on Ann Arbor staging system considering patients symptoms and bone marrow Biopsy (BMB).

**18F-FDG-PET/CT protocol**

18F-FDG-PET/CT is obtained using PET/CT scanner (Discovery STE; GE Healthcare, Boston, USA). Patient was fasted for at least 6 h before the examination. A dose of 5.5 MBq/kg 18F-FDG was injected intravenously 60 min before the scan, patients were asked to rest in a quiet room devoid of distraction to minimize physiological uptake of FDG. Diagnostic CT was performed using the following diameters, 120 kV, 350 mAs, 0.5 s tube rotation, slice thickness 5 mm, 8 mm table feed, and 3 mm incremental reconstruction. A PET emission scan was performed over several bed positions from 5 to 7 for 2 min per bed position with axial field of view of 21.6 cm per bed position and in-plane spatial resolution.
of 2 mm covering the same field of view as with CT. Re-
constructed trans-axial PET and CT images were fused.
These are then reformatted into coronal and sagittal im-
ages, and data were generated.

The maximum SUV in the volume of interest was con-
sidered as the SUV max for the purpose of analysis.

The PET/CT images were interpreted by two experi-
enced radiology consultants (more than 5 years of ex-
perience) with inter-observer agreement.

Reports were compared to those of DWIBS. The
readers were blinded to other modality results.

**WB-MR/DWIBS protocol**

All examinations were performed using a 1.5-T MR
scanner (Achieva Philips Medical SSystem, Netherlands)
Q-body coil with the patient positioned feet first to
cover head, neck, and trunk. Sequences used were T1-
weighted Turbo Spin Echo (TSE) and T2-weighted short
T1 Inversion Recovery (STIR) in coronal orientation to
encompass all anatomical districts from head to the
mid-thigh.

Coronal T1-weighted and STIR and axial DWIBS se-
quences were performed by the following parameters. In
coronal T1-weighted sequence, single-shot turbo spin
echo, TR/TE shortest, slice thickness 6 mm, gap 1 mm,
number of slices for station 39, FOV 350 × 265, acquisi-
tion matrix 208 × 287, reconstruction matrix 512, acqui-
sition voxel size 1.27 × 1.85 × 6.00, reconstructed voxel
size 1.04 × 1.04 × 6.00, number of acquisitions 1, acqui-
sition time/sequence 63 s. In coronal STIR, the following
parameters were used: single-shot turbo spin echo, TR/
TE shortest, inversion time 165 ms, slice thickness 6
mm, gab 1 mm, number of slices for station 39, FOV
350 × 265, acquisition matrix 336 × 121, reconstruction
matrix 512, acquisition voxel size 1.58 × 2.18 × 6.00, re-
constructed voxel size 1.04 × 1.04 × 6.00, number of ac-
quisition 2, acquisition time/sequence 62 s. Both T1W
and STIR images were acquired in free breathing.

DWIBS sequence were acquired in the axial plane, in
free breathing and with the following parameters: single-
shot EPI, TR/TE shortest , inversion time 180 ms, slice
thickness 6 mm, gap 0mm , number of slices for station
44, FOV 530 × 303, acquisition matrix 108 × 61, recon-
structed voxel size 1.5 × 1.50 × 600, half-scan factor
0.627, EPI factor 61, b values 0~1000 s/mm², number of
acquisition 2, acquisition time/sequence 3 min, and 29 s.

DWIBS images were reconstructed on radial (for a
volumetric view) and on coronal planes, with slice thick-
ness 4 mm, gap 1 mm, number of images 44. The recon-
structed images were merged and a coronal whole-body/
DWIBS images were obtained.

ADC maps were automatically generated from DW
images by the MR software.

The WB-MR/DWIBS images were interpreted by two
experienced radiology consultants (more than 5 years of ex-
perience) with inter-observer agreement.

Reports were compared to those of PET/CT. The
readers were blinded to other modality results.

**Images analysis for both modalities**

For standardized comparison of the WB-MR/DWIBS and
PET/CT findings, anatomical regional nodal distribution
was performed into 6 nodal basins cervical, axillary, medi-
astinal, abdominal, pelvic, inguinal, and femoral.

**Standard of reference**

Histopathologically proven data as well as follow-up
period of 10 months.

**WB-MR/DWIBS image analysis**

**Visual analysis**

Lymph-nodes larger than 10 mm in coronal short axis
on T1WI or STIR sequences have been considered posi-
tive. In extra nodal assessment, any areas with altered
signal in T1WI or STIR images showing signal intensity
in DWIBS higher than surrounding tissues were consid-
ered positive for lymphoma infiltration. Signal intensity
of the lesion should be equal or higher than the signal
intensity from the organ with highest intensity in each
station as follows: in the neck, we compared with the
brain; in the chest, we compare with the bone marrow;
in the abdominal region with the kidney; and in the in-
guinal region, with the bone marrow. A diffusely en-
larged spleen (> 13 cm) without focal lesions was also
considered positive.

Bone marrow infiltration was divided into focal or dif-
fuse involvement. Focal disease was diagnosed. If there is
patchy lesion with signal intensity higher than the sur-
rounding bone marrow, the diffuse involvement was de-
defined as wide-spread DWI signal intensity, similar to or
higher than the spleen, corresponding to a hypo-intense
signal in T1WI and hyper-intense signal in T2W-STIR
images.

**Semi-quantitative analysis**

For each lymph node region and organ recorded as posi-
tive on DWI, the lesion showing the lowest signal inten-
sity on ADC maps was identified.

**18F-FDG PET/CT images analysis**

**Visual analysis**

Any focus of elevated FDG metabolism in comparison
with the liver and mediastinum, and not located in areas
of normal FDG uptake, was considered positive.

PET/CT images were assessed for lymphomatous infil-
tration using a 5-point grading system in which the le-
sion uptake was compared to the liver uptake as follows:
score 0 (no uptake), score 1 (lesion uptake < liver uptake), score 2 (lesion uptake = liver uptake), score 3 (lesion uptake > liver uptake), score 4 (intensive lesion uptake that is significantly higher than liver).

Score 0 = the lesion is definitely negative, score 1 = it is probably negative, score 2 = the lesion is equivocal, score 3 = the lesion is probably positive, and score 4 = the lesion is definitely positive.

Quantitative analysis
18F-FDG PET/CT was measured by SUV max, a region of interest was manually placed on each lesion of abnormal uptake and it was calculated.

Results
This prospective study was performed on 32 patients with histopathologically proven lymphoma. Twenty-two patients were diagnosed HL and 10 B-NHL. Among B-NHL, 7 were aggressive and 3 were low grade (indolent). Patients were staged according to Ann Arbor staging system with a higher frequency of stages II and III diseases in both types of lymphoma.

A total of 320 sites (nodal and extra-nodal) have been assessed for lymphoma infiltration using combined radiological and histopathologically proven data as well as follow-up period of 10 months. Comparing with the reference standard, these lesions were divided into lymphomatous infiltration in 81 sites and free of infiltration in 239 sites. For each site, 18F-FDG-PET/CT and WB-MR/DWIBS results were correlated to the reference standard data.

As regards the 18F-FDG PET/CT, 80 lymphomatous infiltration were detected, 78 true positive sites, and 2 false-positive nodal sites. And the 240 free lymphomatous sites were 237 true negative sites and 3 false-negative sites including one splenic and two bone marrow infiltrations which were confirmed by biopsy as shown in Table 1 (Figs. 1 and 2).

As regards the WB-MR/DWIBS, 73 involved sites were noted, 68 true-positive, and 5 false-positive lesions. The remaining 247 depicted as free sites were proved to be 243 true negative and 13 false negative as shown in Table 2.

The overall sensitivity, specificity, PPV, NPV, and accuracy of FDG-PET/CT versus WB-MR/DWIBS in correlation with reference standard data in detection of lymphoma were calculated for PET/CT 96%, 100%, 100%, 80%, and 97% while those of WB-MR/DWIBS were 93%, 76%, 96%, 61%, and 91%, respectively as shown in Table 3.

In attempt to explore the impact on patient’s staging and further management decision, PET/CT and WB-MR/DWIBS staging accuracy was compared with the reference staging of clinico-radiological follow-up, and histopathological results are shown in Table 4.

Our results displayed the following notes:
18F-FDG PET/CT showed the following:

- Better staging of 30 patients out of 32 patients.
- False down-staging of two patients (one patient was staged IV by positive bone marrow biopsy and was missed by FDG-PET/CT, the other one was stage II having focal gastric and splenic involvement but were missed by FDG-PET/CT).
- No up-staging were noted.

WB-MR/DWIBS showed the following:

- Successfully staging of 24 patients out of 32 patients and false results of 8 patients.
- False down-staging of 4 patients (2 patients with stage III by missing splenic infiltration in average size spleen and 2 patients in stages I and II by missing nodal lesions).
- False up-staging of 4 patients (3 patients in stages II and III and one in stage O; all had false-positive splenic infiltration in large-sized spleen).

Discussion
In lymphoma staging, 18F-FDG PET/CT has been used as the most accurate method upon several imaging modalities; however, its sensitivity and specificity vary according to the histological subtype of the disease. WB-MR/DWIBS has emerged as a non-ionizing, functional, non-invasive diagnostic tool [9]. However, the unique in this study is the customized number of examined patients with initial staging and pathologically proven Hodgkin and non-Hodgkin lymphoma.

In the current study, we compared the performance of WB-MR/DWIBS and 18F-FDG PET/CT in 32 histopathologically proven lymphoma patients in diagnosis of lymphoma, assessing its impact on the staging and the therapeutic management.

The overall sensitivity, specificity, PPV, NPV, and accuracy of FDG-PET/CT versus WB-MR/DWIBS in correlation with reference standard data in detection of lymphoma were for PET/CT 96%, 100%, 100%, 80%, and 97% while those of WB-MR/DWIBS were 93%, 76%, 96%, 61%, and 91%, respectively.

| Table 1 Correlation between FDG-PET/CT and the reference data |
|-----------------|-----------------|------------------|
| FDG PET/CT+ve   | 78              | 2                |
| FDG PET/CT−ve   | 3               | 237              |
| Total           | 81              | 239              |

Page 4 of 8
As regards lymph node involvement, the current study shows no false-negative nodal sites were demonstrated by F18-FDG PET/CT in our study compared with the reference standard with sensitivity 100%. Two false-positive inguinal nodal sites by FDG PET/CT proved to be inflammatory in nature.

These correspond with previous studies done by Cristina et al. [10], as the authors concluded that the...
sensitivity of FDG PET/CT in lymph node involvement had reached 100% with no false negative results, and the false-positive nodal sites were explained to be due to the avidity of FDG in inflammatory lymph node.

In the present study, the evaluation of lymph nodal infiltration by WB-MRI/DWIBS depicted one false-positive nodal lesion which could be explained by the high-cellular density of inflammatory lymph nodes; this false-positive nodal site did not change the patient’s staging. However, Van Ufford et al. [11] stated that ADC criteria may have additive value in differentiation of inflammatory from infiltrated nodes.

In our work WB-MR/DWIBS showed 11 false-negative nodal sites in 8 patients. Subsequent false down-staging

Fig. 2  A 35-year-old male with histopathologically proven lymphoma. Axial PET/CT fused image (a), axial CT (b), and axial PET (c) of the mediastinum, and coronal MIP PET (d) showed bulky FDG avid mediastinal lymphadenopathy with SUV max 5.0 producing prominent compression and displacement of the tracheal air column to the right. e Axial DWIBS/ADC map showed restricted diffusion at the mediastinal lymphadenopathy.

Gamal Egyptian Journal of Radiology and Nuclear Medicine (2020) 51:210
occurred in two patients; both patients had small-sized cervical and mediastinal lymph nodes (< 1 cm) that were both FDG avid.

This was agreed with the results of Thomas et al. [12] where they mentioned that the images’ interpretation in WB-MRI/DWIBS is based on size parameter. Size criteria were the major determinant for large number of false-negative lesions. It is common opinion in the literature that the size criterion has significant limitations in any kind of tumor.

As regards the extra-nodal involvement, both methods can identify focal splenic lesions as stated by Nagham et al. [13]; however, PET/CT better evaluate the diffuse splenic involvement compared to the WB-MRI/DWIBS because the later depends on dimensional criterion.

The aforementioned conclusion is in accordance to the present results as the splenic involvement was confirmed in 8 out of the 32 patients. In respect to PET/CT, 7 out of 8 patients with splenic infiltration were confirmed, and 1 patient was missed. However, WB-MRI/DWIBS depicted 2 false-negative and 4 false-positive patients.

In the present study, bone marrow infiltrates was diagnosed in 6 out of the 32 patients. There were no false-positive patients depicted by PET/CT with specificity 100%; however, there were two false-negative patients. Regarding the WB-MRI/DWIBS, our study showed superior merits in evaluation of bone marrow infiltration with sensitivity and specificity of 100%, as the spatial resolution, high contrast, and tissue differentiation are contributing factors. These results correspond with previous studies done by [14, 15].

There are merits and limitations of the current study:
First, the strength of the study includes its prospective nature for addressing a comparison between FDG PET/CT and WB-MRI/DWIBS in detection of nodal and extra nodal lymphoma as well as assessment of their impact on the management.

Its limitation included the small number of patients which were involved. Second, the study was done on heterogeneous group of patients with different pathological subtypes of lymphoma. Third, the accuracy of PET/CT and WB-MRI/DWIBS was not fully established on basis of histopathologically examination as it was not possible to confirm the diagnosis for each lymph node and extra nodal site histopathologically. Alternatively, a clinical and radiological follow-up was used. Future studies with larger cohorts are necessary for better evaluation of the role of WB-MR/DWIBS in lymphoma patients.

**Conclusion**
18F-FDG PET/CT remains the standard reference of imaging in evaluation of lymphoma due to its higher sensitivity and specificity over WB-MR/DWIBS. WB-MRI/DWIBS has a complementary role to PET/CT especially in the context of bone marrow involvement omitting unnecessary bone marrow biopsy.

**Abbreviations**
WB-MR/DWIBS: Whole-body magnetic resonance/diffusion-weighted imaging with background signal suppression; 18F-FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; SUV: Standard uptake value; PPV: Positive predictive value; NPV: Negative predictive value

**Duplicate publication**
The manuscript is original, and it is not under consideration by any other journal.

**Author’s contributions**
The single author is solely responsible to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript. The author read and approved the final manuscript.

### Table 2
Correlation between WR-MR/DWIBS and the reference data

|                | True-positive sites | True-negative sites | Total |
|----------------|---------------------|---------------------|-------|
| MR-DWIBS+ve    | 68                  | 5                   | 73    |
| MR-DWIBS−ve    | 13                  | 234                 | 247   |
| Total          | 81                  | 239                 | 320   |

### Table 3
Overall comparison between 18F-FDG-PET/CT and WB-MR/DWIBS in detection of infiltrated sites in 32 lymphoma patients

|                | PET/CT | DWIBS |
|----------------|--------|-------|
| True +ve       | 27     | 26    |
| False +ve      | 0      | 1     |
| True −ve       | 4      | 3     |
| False −ve      | 1      | 2     |
| Sensitivity    | 96%    | 93%   |
| Specificity    | 100%   | 76%   |
| PPV            | 100%   | 96%   |
| NPV            | 80%    | 61%   |
| Overall accuracy | 97%    | 91%   |

### Table 4
18-FDG PET/CT and WB-MR/DWIBS staging accuracy in correlation with the reference staging

|                | 18-FDG PET/CT | WB-MR/DWIBS |
|----------------|---------------|-------------|
| Patient no.    | %             | %           |
| Accurate-staging | 30            | 24          |
| Up-staging     | 2              | 6           |
| Down-staging   | 0              | 4           |
Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the ethics committee of October 6 University Hospital. Committee’s reference number: not applicable. Consent for participation was signed for each patient.

Consent for publication
Consent for publication was signed for each patient.

Competing interests
The authors declare that they have no competing interests.

Received: 22 May 2020 Accepted: 13 August 2020
Published online: 15 October 2020

References
1. Gali Shapira, Zaltsberg, Nagwa Wilson, Esther Trejo Perez, Lesleigh Abbott, Stephen Dinning, Cassandra Kapoor, Jorge Davila, Barry Smith, Elka Miller (2020) Whole-body diffusion-weighted MRI compared to 18 F FDG PET/CT in initial staging and therapy response assessment of Hodgkin lymphoma in pediatric patients. J Pediatr Hematol Oncol 42(2):217-225
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10-29
3. Wang D, Huo Y, Chen S, Wang H, Ding Y, Zhu X, Ma C (2018) Whole-body MRI versus 18 F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis. J Nucl Med 59(7):1125-1133
4. Gali Shapira, Zaltsberg, Nagwa Wilson, Esther Trejo Perez, Lesleigh Abbott, Stephen Dinning, Cassandra Kapoor, Jorge Davila, Barry Smith, Elka Miller (2020) Whole-body diffusion-weighted MRI compared to 18 F FDG PET/CT in initial staging and therapy response assessment of Hodgkin lymphoma in pediatric patients. J Pediatr Hematol Oncol 42(2):217-225
5. Omur O, Baran Y, Oral A, Ceylan Y (2014) Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol 20:185-192
6. Kirchner, Deuschl C, Schweiger B, Herrmann K et al (2017) Imaging children suffering from lymphoma: an evaluation of different 18F FDG PET/MRI protocols compared to whole body DW-MRI. Eur J Nucl Med Mol Imaging 44(10):1742-1750
7. Regacini R, Puchnick A, Shigueoka DC, Iared W, Lederman HM (2015) Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies. 133(2):141-150. https://doi.org/10.1590/1516-3180.2014.8312810
8. Marafi F, Esmail A, Rasheed R, Alkandari F et al (2017) Novel weight-based dose threshold for 18F NaF PET/CT imaging using advanced PET/CT systems: a potential tool for reducing radiation burden. Nuc Med Commun 38(9):764-770
9. Wang D, Huo Y, Chen S, Wang H, Ding Y, Zhu X, Ma C (2018) Whole-body MRI versus 18F FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis 11: 3597–3608. doi: https://doi.org/10.2147/OTT. S148189
10. Ferrari C, Minoa C, Asabella AN, Nicoletti A, Altini C, Antonica F, Picco M, Guarini A, Maggiali N, Rubini G (2014) Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma 17 Suppl 1:40-9.PMID: 24392468
11. van Ufford HM, Kwee TC, Verhooijen MA et al (2013) Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol 23(8):2271-2278
12. Littooij AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of pediatric lymphoma: prospective comparison to an FDG-PET/CT –based reference standard. Eur Radiol 24(5):1153–1165

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.